PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness

Abstract Programmed death ligand-1 (PD-L1), a promising antitumor target, has proven clinical value against many malignancies. However, the PD-L1 content of Xp11.2 translocation renal cell carcinoma (Xp11.2 RCC) and its correlation with clinical outcomes remain unclear. This study aimed to investiga...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kun Chang, Yuanyuan Qu, Bo Dai, Jian-Yuan Zhao, Hualei Gan, Guohai Shi, Yiping Zhu, Yijun Shen, Yao Zhu, Hailiang Zhang, Dingwei Ye
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/1bdfc57c88ee4522a2dca323ac365b0a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1bdfc57c88ee4522a2dca323ac365b0a
record_format	dspace
spelling	oai:doaj.org-article:1bdfc57c88ee4522a2dca323ac365b0a2021-12-02T16:08:11ZPD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness10.1038/s41598-017-02005-72045-2322https://doaj.org/article/1bdfc57c88ee4522a2dca323ac365b0a2017-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-02005-7https://doaj.org/toc/2045-2322Abstract Programmed death ligand-1 (PD-L1), a promising antitumor target, has proven clinical value against many malignancies. However, the PD-L1 content of Xp11.2 translocation renal cell carcinoma (Xp11.2 RCC) and its correlation with clinical outcomes remain unclear. This study aimed to investigate PD-L1 expression in Xp11.2 RCC and to assess its prognostic value. Formalin-fixed paraffin-embedded specimens from 36 adult patients that were histologically confirmed (by fluorescence in situ hybridization) were subjected to immunohistochemical analysis. Of the 36 Xp11.2 RCC patients, 9 (25.0%) had tumors with positive PD-L1 expression and 27 (75.0%) had tumors with negative PD-L1 expression. Positive PD-L1 expression correlated with advanced tumor stage (P = 0.001), regional lymph node metastasis (P < 0.001), and distant metastasis (P < 0.001). A multivariate analysis identified positive PD-L1 expression was an independent adverse prognostic factor for both progression free survival (hazard ratio: 3.7, P = 0.018) and overall survival (hazard ratio: 4.5, P = 0.034). The median PFS and OS for the whole cohort were 13.0 months (95% confidence interval [CI], 9.4–16.6 months) and 36.0 months (95% CI, 23.9–48.1 months), respectively. Our findings suggest that positive PD-L1 expression is indicative of worse clinical outcome in Xp11.2 RCC. Further studies are needed to explore the potential efficacy of targeting PD-L1 in Xp11.2 RCC.Kun ChangYuanyuan QuBo DaiJian-Yuan ZhaoHualei GanGuohai ShiYiping ZhuYijun ShenYao ZhuHailiang ZhangDingwei YeNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-7 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Kun Chang Yuanyuan Qu Bo Dai Jian-Yuan Zhao Hualei Gan Guohai Shi Yiping Zhu Yijun Shen Yao Zhu Hailiang Zhang Dingwei Ye PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness
description	Abstract Programmed death ligand-1 (PD-L1), a promising antitumor target, has proven clinical value against many malignancies. However, the PD-L1 content of Xp11.2 translocation renal cell carcinoma (Xp11.2 RCC) and its correlation with clinical outcomes remain unclear. This study aimed to investigate PD-L1 expression in Xp11.2 RCC and to assess its prognostic value. Formalin-fixed paraffin-embedded specimens from 36 adult patients that were histologically confirmed (by fluorescence in situ hybridization) were subjected to immunohistochemical analysis. Of the 36 Xp11.2 RCC patients, 9 (25.0%) had tumors with positive PD-L1 expression and 27 (75.0%) had tumors with negative PD-L1 expression. Positive PD-L1 expression correlated with advanced tumor stage (P = 0.001), regional lymph node metastasis (P < 0.001), and distant metastasis (P < 0.001). A multivariate analysis identified positive PD-L1 expression was an independent adverse prognostic factor for both progression free survival (hazard ratio: 3.7, P = 0.018) and overall survival (hazard ratio: 4.5, P = 0.034). The median PFS and OS for the whole cohort were 13.0 months (95% confidence interval [CI], 9.4–16.6 months) and 36.0 months (95% CI, 23.9–48.1 months), respectively. Our findings suggest that positive PD-L1 expression is indicative of worse clinical outcome in Xp11.2 RCC. Further studies are needed to explore the potential efficacy of targeting PD-L1 in Xp11.2 RCC.
format	article
author	Kun Chang Yuanyuan Qu Bo Dai Jian-Yuan Zhao Hualei Gan Guohai Shi Yiping Zhu Yijun Shen Yao Zhu Hailiang Zhang Dingwei Ye
author_facet	Kun Chang Yuanyuan Qu Bo Dai Jian-Yuan Zhao Hualei Gan Guohai Shi Yiping Zhu Yijun Shen Yao Zhu Hailiang Zhang Dingwei Ye
author_sort	Kun Chang
title	PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness
title_short	PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness
title_full	PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness
title_fullStr	PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness
title_full_unstemmed	PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness
title_sort	pd-l1 expression in xp11.2 translocation renal cell carcinoma: indicator of tumor aggressiveness
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/1bdfc57c88ee4522a2dca323ac365b0a
work_keys_str_mv	AT kunchang pdl1expressioninxp112translocationrenalcellcarcinomaindicatoroftumoraggressiveness AT yuanyuanqu pdl1expressioninxp112translocationrenalcellcarcinomaindicatoroftumoraggressiveness AT bodai pdl1expressioninxp112translocationrenalcellcarcinomaindicatoroftumoraggressiveness AT jianyuanzhao pdl1expressioninxp112translocationrenalcellcarcinomaindicatoroftumoraggressiveness AT hualeigan pdl1expressioninxp112translocationrenalcellcarcinomaindicatoroftumoraggressiveness AT guohaishi pdl1expressioninxp112translocationrenalcellcarcinomaindicatoroftumoraggressiveness AT yipingzhu pdl1expressioninxp112translocationrenalcellcarcinomaindicatoroftumoraggressiveness AT yijunshen pdl1expressioninxp112translocationrenalcellcarcinomaindicatoroftumoraggressiveness AT yaozhu pdl1expressioninxp112translocationrenalcellcarcinomaindicatoroftumoraggressiveness AT hailiangzhang pdl1expressioninxp112translocationrenalcellcarcinomaindicatoroftumoraggressiveness AT dingweiye pdl1expressioninxp112translocationrenalcellcarcinomaindicatoroftumoraggressiveness
_version_	1718384580208099328

PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness

Ejemplares similares